Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a

Sakashita, Masafumi; Yamada, Tetsuji; Imoto, Yoshimasa; Hirota, Tomomitsu; Tamari, Mayumi; Ito, Yatsuji; Kubo, Shigeru; Osawa, Yusuke; Takahashi, Noboru; Fujieda, Shigeharu

doi:10.1016/j.cyto.2015.03.019

Cited by 9 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of our study revealed that the serum IL-17 levels decreased after 6 months of cluster immunotherapy compared with levels measured before immunotherapy and compared with levels taken from those who did not receive immunotherapy ( Table 4 ). This result agreed with Ding et al , 30 who showed that the mechanism of action of sublingual immunotherapy (SLIT) for the treatment of AR and asthma may be associated with inhibition of IL-17 expression and also agreed with Sakashita et al , 31 who showed that long-term SLIT reduced the serum levels of IL-17. So, the serum level of IL-17A might prove useful as a biologic parameter to ascertain the effectiveness of SLIT.…”

Section: Discussionsupporting

confidence: 91%

The Study of a Possible Correlation between Serum Levels of Interleukin 17 and Clinical Severity in Patients with Allergic Rhinitis

Aly

Tabbakh

Heissam

et al. 2017

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

Introduction:Allergic rhinitis (AR) is one of the most common allergic diseases, which affects ∼20% of the world's population. T-helper (Th) type 2 cells produce interleukin (IL) 4 and IL-13, and mediate allergic responses, and these cytokines have been extensively studied as key players in the atopic airway diseases. However, the involvement of Th17 cells and IL-17 in AR has not been clearly examined.Aim:To reevaluate AR clinical severity with serum IL-17, whether IL-17 affects the disease alone or in contribution with the atopic predisposition.Patients and Methods:During an 18-month period, 39 individuals were divided into three groups: A, (13 control), B (13 with mild-to-moderate AR), and C (13 with severe AR). Both group B and group C patients (26) were subjected to clinical examination and allergy skin testing, and to measurement of both total serum immunoglobulin E (IgE) and IL-17 levels. Eleven patients with AR then were exposed to 6 months of cluster immunotherapy, whereas the rest of the patients were not exposed.Results:Revealed a significant elevation of serum IL-17 levels with an associated increase in serum IgE in the patients with AR compared with controls and revealed that the serum levels of both total serum IgE and IL-17 decreased significantly after cluster immunotherapy.Conclusion:These preliminary results added new data about the use of injective immunotherapy as well as reported on the use of sublingual immunotherapy.

show abstract

Section: Discussionsupporting

confidence: 91%

The Study of a Possible Correlation between Serum Levels of Interleukin 17 and Clinical Severity in Patients with Allergic Rhinitis

Aly

Tabbakh

Heissam

et al. 2017

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

show abstract

“…Furthermore, no clear relationship between serum cytokines and clinical outcome of AIT has been demonstrated. Besides addressing interleukins, numerous studies during AIT investigated chemokines CCR3 (unchanged) and CCR4 (increased) and other original serum markers, like adiponectin (unchanged), apolipoprotein A‐IV (increased), beta thromboglobulin (unchanged), complement factors C3a and 5a (decreased), C4a (increased), ECP (unchanged), eotaxin (increased/decreased), soluble HLA molecules (unchanged), leptin (unchanged or increased), signalling lymphocytic activation molecule (increased), thymus and activation‐regulated chemokine (TARC) (increased), TRAIL (reduced), transthyretin (increased) to tryptase (unchanged). Importantly, none of these markers showed any correlation with the clinical response.…”

Section: Resultsmentioning

confidence: 99%

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Shamji

Kappen

Akdiş

et al. 2017

Allergy

305

367

View full text Add to dashboard Cite

Background: Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma. It is important to note that due to the complex interaction between patient, allergy triggers, symptomatology and vaccines used for AIT, some patients do not respond optimally to the treatment. Furthermore, there are no validated or generally accepted candidate biomarkers that are predictive of the clinical response to AIT. Clinical management of patients receiving AIT and efficacy in randomised controlled trials for drug development could be enhanced by predictive biomarkers. Method: The EAACI taskforce reviewed all candidate biomarkers used in clinical trials of AR patients with/without asthma in a literature review. Biomarkers were grouped into seven domains: (i) IgE (total IgE, specific IgE and sIgE/Total IgE ratio), (ii) IgG-subclasses (sIgG1, sIgG4 including SIgE/IgG4 ratio), (iii) Serum inhibitory activity for IgE (IgE-FAB and IgE-BF), (iv) Basophil activation, (v) Cytokines and Chemokines, (vi) Cellular markers (T regulatory cells, B regulatory cells and dendritic cells) and (vii) In vivo biomarkers (including provocation tests?). Results: All biomarkers were reviewed in the light of their potential advantages as well as their respective drawbacks. Unmet needs and specific recommendations on all seven domains were addressed.

show abstract

“…It is therefore possible that the JCPspecific IgE level might decrease if the trial period were extended. Serum IL-17A, SCCA2, periostin, saliva, and pathogenic Th2 cells have been reported as potentially useful clinical biomarkers for evaluating the efficacy of SLIT for JCP [17][18][19]. Periostin is highly expressed in chronic inflammatory diseases like asthma, chronic rhinosinusitis, atopic dermatitis, and allergic conjunctivitis [20], and has emerged as a useful biomarker of allergic diseases.…”

Section: Discussionmentioning

confidence: 99%

Serum Concentrations of Antigen-Specific IgG4 in Patients with Japanese Cedar Pollinosis

et al. 2021

View full text Add to dashboard Cite

Purpose: To elucidate the usefulness of Japanese cedar pollen (JCP)-specific antigen-specific immunoglobulin (IgG) 4 as a biomarker for predicting the efficacy of sublingual immunotherapy for cedar pollen-induced allergic rhinitis. Methods: We divided a total of 105 cases with Japanese cedar pollinosis into three groups: “SLIT Successful,” SLIT Unsatisfactory,” and “SCIT” groups. The SLIT group patients were treated with JCP Droplet (Torii Pharmaceutical Co. Ltd., Tokyo, Japan) for one year from 2015 and were divided into two groups, the SLIT Successful group or the SLIT Unsatisfactory group. The SLIT Successful group (n = 16) were subjects treated by SLIT only, who were able to experience control of their naso-ocular symptoms without the need for antiallergic rescue agents during the peak season of atmospheric pollen. The SLIT Unsatisfactory group (n = 76) comprised subjects treated with SLIT only, who did not respond successfully, and were administered with rescue agents to control their naso-ocular symptoms. The SCIT group had been treated with standardized JCP extract (Torii Pharmaceutical Co., Ltd., Tokyo, Japan) for three years from 2012, and were also able to experience control of their symptoms during the peak pollen season without the need for antiallergic rescue agents. We determined the serum level of JCP-specific immunoglobulin E (IgE), IgG, and IgG4 used in the 3gAllergy-specific IgE assay (3gAllergy). The serum levels of periostin and SCCA2 were measured using established ELISA procedures (clones SS18A and SS17B; Shino-Test, Japan) following the manufacturer’s instructions. We then made ROC curves for each group and assessed which index was best able to predict the efficacy of sublingual immunotherapy. Results: Serum JCP-specific IgE was significantly lower in the SCIT group than in the SLIT Successful group and the SLIT Unsatisfactory group (p < 0.05). Serum JCP-specific IgG was significantly higher in the SCIT group and the SLIT Successful group than in the SLIT Unsatisfactory group (p < 0.05). Serum JCP-specific IgG4 was also significantly higher in the SCIT group and the SLIT Successful group than in the SLIT Unsatisfactory group (p < 0.05). There was no significant difference among serum levels of periostin in the SCIT group, the SLIT Successful group, or the SLIT Unsatisfactory group. There was also no significant difference in SCCA2 among the three groups. In terms of ROC curves, a serum JCP-specific IgG4 value greater than 989.5 UA/mL showed the best sensitivity (93.3%) and specificity (94.7%) (p < 0.05) among other parameters. Conclusions: The serum JCP-specific IgG4 level is significantly correlated with the clinical efficacy of SLIT. Serum JCP-specific IgG4 cutoff levels greater than 989.5 UA/mL were correlated with an effective clinical response to SLIT, with a sensitivity of 93.3% and a specificity of 94.7%.

show abstract

Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a

Cited by 9 publications

References 32 publications

The Study of a Possible Correlation between Serum Levels of Interleukin 17 and Clinical Severity in Patients with Allergic Rhinitis

The Study of a Possible Correlation between Serum Levels of Interleukin 17 and Clinical Severity in Patients with Allergic Rhinitis

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Serum Concentrations of Antigen-Specific IgG4 in Patients with Japanese Cedar Pollinosis

Contact Info

Product

Resources

About